T. D. Scobey

This study develops a trivalent RBD nanoparticle vaccine that protects mice against both merbecovirus and sarbecovirus challenges, including SARS-CoV, MERS-CoV, and SARS-CoV-2.

This study evaluates the antiviral efficacy of GS-5245 against multiple SARS-CoV-2 variants and other coronaviruses, showing broad in vitro activity and protective effects in animal models.

The paper identifies a multitrait locus on mouse Chromosome 9 that regulates SARS-CoV, SARS-CoV-2, and bat sarbecovirus disease severity, with candidate genes CCR9 and CXCR6.

This study shows that SARS-CoV-2 vaccines induce neutralizing antibodies against SARS-CoV-1, SARS-CoV-2, and batCoVs in monkeys.

This study examines SARS-CoV-2 neutralizing and infection-enhancing antibodies, showing in vitro enhancement does not always lead to in vivo disease enhancement, but can cause increased lung inflammation in monkeys.

This study engineers an antibody, ADG-2, that broadly neutralizes SARS-CoV and SARS-CoV-2 in mice, offering protection against respiratory disease and viral replication.

This study shows that proteolytic cleavage, not receptor binding, is the main barrier for two MERS-like bat coronaviruses to infect human cells, and that trypsin treatment can overcome this barrier.